CDH20

Across TCGA pan-cancer cohorts, CDH20 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CDH20 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CDH20 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDH20 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

COAD, SCLC, and SKCM are the cancer types where CDH20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	III,IV	0.045	0.781	<.001	24	view →
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	15	view →
SKCM	OS	Median	II,III,IV	0.947	0.828	.013	7	view →
UCEC	DFS	Median	II,III,IV	0.922	0.437	.026	6	view →
LIHC	DFS	Median	All	0.149	0.555	.024	6	view →
LUAD	DFS	Median	II,III,IV	0.890	0.236	.046	3	view →
HNSC	DFS	Median	All	1.000	0.317	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CDH20–COAD (OS)

Open the COAD breakdown →